Literature DB >> 20456825

Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.

Maryam Noubarani1, Fariborz Keyhanfar, Manijeh Motevalian, Masoud Mahmoudian.   

Abstract

PURPOSE: To develop a simple and rapid HPLC method for measuring of four proton-pump inhibitors (PPIs), omeprazole (OPZ), pantoprazole (PPZ), lansoprazole (LPZ) and rabeprazole (RPZ) concentrations in human plasma.
METHODS: Following a single step liquid-liquid extraction analytes along with an internal standard (IS) were separated using an isocratic mobile phase of phosphate buffer (10 mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 with triethylamine) at flow rate of 1 mL/min on reverse phase TRACER EXCEL 120 ODS-A column at room temperature.
RESULTS: Total analytical run time for selected PPIs was 10 min. The assays exhibited good linearity (r(2)>0.99) over the studied range of 20 to 2500 ng/mL for OPZ, 20 to 4000 ng/mL for PPZ, 20 to 3000 ng/mL for LPZ and 20 to 1500 ng/mL for RPZ. The recovery of method was equal or greater than 80% and lower limit of quantification (LLOQ) was 20 ng/mL for four PPIs. Coefficient of variation and error at all of the intra-day and inter-day assessment were less than 9.2% for all compounds.
CONCLUSIONS: The results indicated that this method is a simple, rapid, precise and accurate assay for determination of four PPIs concentrations in human plasma. This validated method is sensitive and reproducible enough to be used in pharmacokinetic studies and also is time- and cost-benefit when selected PPIs are desired to be analyzed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456825     DOI: 10.18433/j3gp4q

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  6 in total

1.  Development and validation of a UPLC method for rapid and simultaneous analysis of proton pump inhibitors.

Authors:  Richard T Addo; Kenneth Davis; Ruhi Ubale; Joel S Owen; E Blake Watkins
Journal:  AAPS PharmSciTech       Date:  2014-08-27       Impact factor: 3.246

2.  Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.

Authors:  Fuchao Chen; Xudong He; Baoxia Fang; Sicen Wang
Journal:  Drug Des Devel Ther       Date:  2020-12-24       Impact factor: 4.162

3.  Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.

Authors:  Neha Deshpande; Sharanya V; Ravi Kanth V V; Murthy H V V; Sasikala M; Rupa Banerjee; Manu Tandan; Nageshwar Reddy D
Journal:  Meta Gene       Date:  2016-06-18

4.  TLC-Densitometry for Determination of Omeprazole in Simple and Combined Pharmaceutical Preparations.

Authors:  Wioletta Parys; Alina Pyka-Pająk
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-18

5.  A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.

Authors:  Yiting Yang; Zexin Zhang; Ping Li; Weimin Kong; Xiaodong Liu; Li Liu
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

6.  Analytical method development and validation of simultaneous estimation of rabeprazole, pantoprazole, and itopride by reverse-phase high-performance liquid chromatography.

Authors:  Senthamil Selvan Perumal; Sanmuga Priya Ekambaram; Samundeswari Raja
Journal:  J Food Drug Anal       Date:  2014-10-28       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.